Peyre F, Verdoux H, Bourgeois M
Unité d'Investigations Cliniques Approfondies, C.H.S. Charles Perrens, Bordeaux.
Encephale. 1992 Jan;18 Spec No 1:73-4.
The study of a sample of 189 inpatients with the diagnostic of Major Depressive Disorder (DSM III-R) treated with fluvoxamine showed: a good compromise efficacy/tolerance in 75% of cases; an interruption of treatment in 25% of cases, schematically divided in early gastric intolerance and in late resistance. 2.5% of manic switches have been observed and contribued, with this pattern of good results, to confirm the major antidepressant activity and good tolerance of fluvoxamine.
对189例诊断为重度抑郁症(DSM III-R)且接受氟伏沙明治疗的住院患者进行的研究显示:75%的病例疗效/耐受性良好;25%的病例中断治疗,大致分为早期胃部不耐受和后期耐药。观察到2.5%的患者出现躁狂转换,结合这种良好的结果模式,证实了氟伏沙明具有主要的抗抑郁活性和良好的耐受性。